Center for Interventional Oncology

介入肿瘤中心

• 批准号: 8554178
• 负责人: Bradford J Wood
• 金额: $ 113.71万
• 依托单位: DIVISION OF BASIC SCIENCES - NCI
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/8554178
• 关键词: Ablation; Address; Arteries; Artificial nanoparticles; Biological Markers; Biomedical Engineering; Biopsy; Cancer Patient; Catheters; Clinical; Collaborations; Development; Devices; Diagnosis; Discipline; Disease; Dose; Drug Delivery Systems; Education; Emerging Technologies; Energy-Generating Resources; Engineering; Environment; Focused Ultrasound Therapy; Freezing; Goals; Heating; Home environment; Human; Image; Imagery; Imaging Device; Imaging technology; Institutes; Intervention; Interventional radiology; Intramural Research Program; Investigation; Investigational Drugs; Lasers; Local Therapy; Localized Malignant Neoplasm; Location; Magnetic Resonance Imaging; Malignant Neoplasms; Medical; Medical Oncology; Medicine; Methods; Modeling; Molecular Probes; Multimodal Imaging; National Cancer Institute; Needles; Neoplasms; Oncologist; Organ; Patient Care; Patients; Pharmaceutical Preparations; Physicians; Positioning Attribute; Positron-Emission Tomography; Procedures; Prostate; Radiation; Radiation Oncology; Radiology Specialty; Radiosurgery; Reporting; Research; Research Personnel; Science; Scientist; Screening for cancer; Surgical Oncologist; Surgical Oncology; System; Techniques; Technology; Time; Tissues; Training; Training Programs; Training and Education; Translating; Translational Research; Translations; Ultrasonography; United States National Institutes of Health; Urologic Oncology; Veins; X-Ray Computed Tomography; base; bench to bedside; bioimaging; cancer therapy; chemotherapy; combination cancer therapy; cost effective; drug discovery; imaging modality; meetings; microwave electromagnetic radiation; minimally invasive; multidisciplinary; nanoparticle; new technology; novel; oncology; planetary Atmosphere; programs; radiofrequency; radiologist; response; robot assistance; sound; technology/technique; therapeutic target; tool; tumor; urologic

The NIH Center for Interventional Oncology is an interdisciplinary effort with the primary goal of developing and better defining novel local, regional, or combination cancer therapies in patients with localized or organ-confined neoplasms. The mechanisms by which this goal will be achieved will include collaborations between imaging scientists, interventional radiologists, oncologists (surgical, medical, radiation, or urological), biologists and engineers. The CIO will provide a translational environment wherein clinical shortcomings in oncology are identified, then addressed by a collaborative team that develop novel technologies and techniques. Minimally invasive therapies are often less costly, safer, and easy to translate and broadly apply in the setting of the NIH Clinical Center and Intramural Research Program. The new Center for Interventional Oncology (CIO) was established in late FY 09 at the NIH Clinical Center (CC) to develop and translate image-guided technologies for localized cancer treatments. The Center is a collaboration involving the CC and the National Cancer Institute (NCI), [and to lesser extent the National Institute of Bioimaging and Bioengineering (NIBIB)]. The Center will draw on the strengths of each institute to investigate how imaging technologies and advanced devices can diagnose and treat localized cancers in ways that are precisely targeted and minimally or non-invasive. It will also help bridge the gap between diagnosis and therapy, and between emerging technology and procedural medicine. Advanced imaging methods have ushered in an era of earlier detection of cancers that are frequently localized to a single organ or region. Interventional oncology often provides cancer patients with local or regional treatment options to augment the standard cancer treatment options: systemic chemotherapy, surgery, and radiation. CIO investigators will leverage the interdisciplinary, translational environment at the CC to investigate and optimize how and when to combine drugs, devices, and multimodal imaging navigation. For example, "activatable" drugs can be injected in a vein or artery, then deployed directly in the tumor with needles or catheters using "medical GPS"a technique that enables the physician to navigate through the body with real-time visualization using the latest advanced imaging technologies, such as magnetic resonance imaging (MRI), positron emission tomography (PET), computed tomography (CT), or ultrasound. Images captured earlier can be reused to guide devices delivering targeted therapy to the location of the disease, making the procedure more cost-effective because it doesn't require the system used to record the first image to be physically present. A prior prostate MRI, for example, can be used to help with guided biopsy or focal ablation by using a "medical GPS"-enabled needle and ultrasound, without requiring, occupying or tying up an MRI system during the procedure. In another example, a thin needle or sound waves can be used to ablate tumors and enhance targeted drug delivery. Energy sources include high-intensity focused ultrasound, freezing, microwaves, laser, and radiofrequency. Researchers also expand investigations into image-guided drug delivery or image-guided "dose painting," where the image can be used to prescribe a particular drug dose to a specific region, by combining targeted, activate-able drugs with localized energy or heat to deploy the drug within specially engineered nano-particles. The Center provides a forum to encourage collaborations among researchers and patient-care experts in medical, surgical, urologic, and radiation oncology and interventional radiology. The CC provides an exceptional environment for this type of collaborative translational research and patient care. Other major program components include the development of new image-guided methods for personalized drug investigations (or tracking tissue responses to investigational drugs during drug discovery) and first-in-human investigations involving new drugs, devices, image-guided robotic assistance, molecular probes, and nanoparticles. Many oncologists are not currently familiar with, nor trained in, image based, localized treatment approaches. At the same time, interventional radiologists may lack formal training in oncology. Therefore, education and cross-training is another important part of the program. Significant gaps exist between the various disciplines, between research efforts and patient care, and between diagnosis and treatment. The gaps may be integrated through advanced image methods for localized therapy. Further, cross-disciplinary training programs in interventional oncology suited to these early disease detect & treat paradigms do not yet exist, but would augment existing programs and underline the unique translational atmosphere at the NIH, where bench-to-bedside is the rule. The CIO's collaborative activities are guided by a steering committee with input from multiple ICs with the home-base in the Clinical Centers Radiology and Imaging Sciences Department. Specific aims include: 1. Develop training and education in Interventional Oncology 2. Develop novel image-guided methods for smart biopsy and biomarker procurement to support targeted therapeutics 3. Support patient care using novel minimally invasive Interventional Oncology techniques 4. Pursue research in novel techniques and technologies in Interventional Oncology This new program is ideally and uniquely positioned to provide an interdisciplinary environment that combines training, patient care, and translational research to accelerate progress in interventional oncology and molecularly targeted interventions. The focus is upon translational models, translational tools, and actual deliverables of translation of multidisciplinary paradigms that meet specific clinical needs.

美国国立卫生研究院介入肿瘤学中心是一个跨学科的机构，其主要目标是开发和更好地定义针对局限性或器官局限性肿瘤患者的新型局部、区域或组合癌症疗法。实现这一目标的机制将包括影像科学家、介入放射科医生、肿瘤学家（外科、内科、放射或泌尿科）、生物学家和工程师之间的合作。首席信息官将提供一个转化环境，识别肿瘤学的临床缺陷，然后由开发新技术和工艺的协作团队解决。微创疗法通常成本较低、更安全、易于转化，并广泛应用于 NIH 临床中心和校内研究项目。新的介入肿瘤学中心 (CIO) 于 2009 财年末在 NIH 临床中心 (CC) 成立，旨在开发和转化用于局部癌症治疗的图像引导技术。该中心是 CC 和国家癌症研究所 (NCI) [以及较小程度上的国家生物成像和生物工程研究所 (NIBIB)] 的合作项目。该中心将利用每个研究所的优势，研究成像技术和先进设备如何以精确靶向、微创或无创的方式诊断和治疗局部癌症。它还将有助于弥合诊断和治疗之间以及新兴技术和程序医学之间的差距。先进的成像方法开创了早期检测癌症的时代，这些癌症通常局限于单个器官或区域。介入肿瘤学通常为癌症患者提供局部或区域治疗选择，以增强标准癌症治疗选择：全身化疗、手术和放疗。 CIO 研究人员将利用 CC 的跨学科、转化环境来研究和优化如何以及何时结合药物、设备和多模态成像导航。例如，“可激活”药物可以注射到静脉或动脉中，然后使用“医用 GPS”技术通过针或导管直接部署在肿瘤中，该技术使医生能够使用最新的实时可视化技术在体内进行导航。先进的成像技术，例如磁共振成像 (MRI)、正电子发射断层扫描 (PET)、计算机断层扫描 (CT) 或超声波。早期捕获的图像可以重复使用，以引导设备向疾病位置提供靶向治疗，从而使该过程更具成本效益，因为它不需要用于记录第一张图像的系统实际存在。例如，先前的前列腺 MRI 可用于通过使用“医用 GPS”针和超声波来帮助引导活检或局部消融，而无需在手术过程中占用或束缚 MRI 系统。在另一个例子中，细针或声波可用于消融肿瘤并增强靶向药物输送。能源包括高强度聚焦超声波、冷冻、微波、激光和射频。研究人员还扩大了对图像引导药物输送或图像引导“剂量绘画”的研究，其中图像可用于通过将靶向的、可激活的药物与局部能量或热量相结合来向特定区域开出特定的药物剂量。将药物部署在专门设计的纳米颗粒中。该中心提供了一个论坛，鼓励医学、外科、泌尿外科、放射肿瘤学和介入放射学领域的研究人员和患者护理专家之间的合作。 CC 为此类合作转化研究和患者护理提供了特殊的环境。其他主要项目组成部分包括开发用于个性化药物研究的新图像引导方法（或在药物发现过程中跟踪研究药物的组织反应）以及涉及新药物、设备、图像引导机器人辅助、分子探针的首次人体研究和纳米粒子。许多肿瘤学家目前不熟悉基于图像的局部治疗方法，也没有接受过相关培训。与此同时，介入放射科医生可能缺乏肿瘤学方面的正式培训。因此，教育和交叉培训是该计划的另一个重要组成部分。不同学科之间、研究工作和患者护理之间以及诊断和治疗之间存在着巨大差距。这些间隙可以通过先进的图像方法进行整合以进行局部治疗。此外，适合这些早期疾病检测和治疗范式的介入肿瘤学跨学科培训项目尚不存在，但将增强现有项目并强调 NIH 独特的转化氛围，从实验室到临床是规则。 CIO 的协作活动由指导委员会指导，并听取总部位于临床中心放射学和影像科学部的多个 IC 的意见。具体目标包括： 1. 开展介入肿瘤学培训和教育 2. 开发用于智能活检和生物标志物采购的新型图像引导方法，以支持靶向治疗 3. 使用新型微创介入肿瘤学技术支持患者护理 4. 开展新技术研究介入肿瘤学和技术 这个新项目具有理想且独特的定位，旨在提供一个结合培训、患者护理和转化研究的跨学科环境，以加速介入肿瘤学的进展肿瘤学和分子靶向干预措施。重点是满足特定临床需求的多学科范式翻译的转化模型、转化工具和实际交付成果。